Final results of a randomized phase II GELA/LYSA study of rituximab plus ACVBP or CHOP, using a PET-driven consolidation strategy, in patients with high-risk diffuse large B-cell lymphoma (DLBCL).

被引：3

作者：

Casasnovas, Rene-Olivier

Ysebaert, Loic

Thieblemont, Catherine

Coiffier, Bertrand

Bologna, Serge

Lepeu, Gerard

Delmer, Alain

Plantier, Isabelle

Gabarre, Jean

Andre, Marc

Senecal, Delphine

Fruchart, Christophe

Meignan, Michel

Berriolo-Riedinger, Alina

Bardet, Stephane

Molina, Thierry Jo

Jais, Jean-Philippe

Haioun, Corinne

Tilly, Herve

Morschhauser, Franck

机构：

[1] Hop Le Bocage, Dijon, France

[2] CHU Toulouse, Toulouse, France

[3] Hop St Louis, AP HP, Paris, France

[4] Lyon Sud Univ Hosp, Pierre Benite, France

[5] Ctr Hosp Univ, Nancy, France

[6] Ctr Hosp Avignon, Avignon, France

[7] Hop Robert Debre, Reims, France

[8] CH Roubaix, Roubaix, France

[9] Hop La Pitie Salpetriere, Paris, France

[10] Ctr Hosp Univ Mt Godinne, Dinant, Belgium

[11] CH Chambery, Chambery, France

[12] Ctr Francois Baclesse, F-14021 Caen, France

[13] Hop Henri Mondor, F-94010 Creteil, France

[14] Ctr Georges Francois Leclerc, Dept Nucl Med, Dijon, France

[15] Hop Hotel Dieu, Paris, France

[16] Univ Paris 05, Paris, France

[17] Ctr Henri Becquerel, F-76038 Rouen, France

[18] Hop Claude Huriez, Lille, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期

关键词：

D O I：

10.1200/jco.2014.32.15_suppl.8503

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8503

引用

页数：1